Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced that CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City. The fireside chat is scheduled for Sept. 16 at 8:30 a.m. EDT and will be webcast live, with a replay available on the Events & Presentations page of the company's investor relations website. The full press release can be accessed at https://ibn.fm/r0jfC.
The invitation to present at one of the healthcare industry's most prestigious investor conferences underscores Helus Pharma's rising profile in the mental health treatment space. Morgan Stanley's Global Healthcare Conference attracts top executives, investors, and analysts, providing a platform for companies to showcase their strategic vision and clinical progress. For Helus Pharma, this appearance offers a critical opportunity to engage with institutional investors and potential partners at a time when the demand for innovative mental health therapies is greater than ever.
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company committed to helping minds heal by developing proprietary novel serotonergic agonists (NSAs)—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. These NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. The company's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Another candidate, HLP004, is in Phase 2 for generalized anxiety disorder.
The significance of this announcement lies in the validation it brings to Helus Pharma's approach. Breakthrough Therapy Designation from the FDA is reserved for drugs that may offer substantial improvement over existing therapies, and it can expedite development and review. With class-leading data, Helus Pharma aims to improve the treatment landscape through NSAs that provide durable improvements in mental health. The company operates in Canada, the United States, the United Kingdom, and Ireland, positioning it to potentially address mental health crises across multiple major markets.
For investors, the fireside chat represents a chance to hear directly from CEO Michael Halstead about the company's progress and upcoming milestones. The webcast and replay ensure that both current and potential shareholders can access the discussion. More information about Helus Pharma is available at www.helus.com, and the latest news and updates relating to HELP can be found in the company's newsroom at https://ibn.fm/HELP.
The mental health treatment sector has seen increased investment and innovation in recent years, yet significant gaps remain. Helus Pharma's participation in the Morgan Stanley conference highlights the growing recognition of psychedelic-inspired medicines as a serious area of pharmaceutical research. As the company advances its pipeline, its ability to attract investor attention and capital could accelerate the development of new therapies for millions of patients. This announcement, therefore, is not merely a scheduling note; it signals Helus Pharma's ambition to be a leader in a rapidly evolving field that holds promise for transforming mental health care.
